The authors also explained that one reason for this conversion was that mTOR inhibitors suppress early production of B cells and reduce the population of antigen-specific memory B cells, which would be expected to reduce cross-reactive antibody production and thus antibody-dependent potentiation in patients with COVID-19 [26]. The gene discussed is MTOR; the disease is COVID-19.